Skip to main content
SpringerLink
Log in

Melanoma brain metastases: the impact of nodal disease

  • Research Paper
  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

Brain metastases (BMs) are a major source of mortality and morbidity in patients with melanoma. This study assesses prognostic nodal factors in patients with nodal metastatic melanoma with respect to the development of BMs. The aim was to identify a high risk subset that may benefit from brain directed management. Prospective surgical and clinical trial databases identified patients who had had nodal dissections and were seen through the Princess Alexandra Hospital Melanoma clinic between August 1995 and June 2010. Patient data was collected and event data was updated from medical imaging and clinical records. The primary endpoint was the rate of development of BMs. 474 patients were identified as having nodal dissections. Two hundred and eighty-seven patients (61 %) were male with a median age of 52 (39–66). The most common nodal dissection site was axilla 190 (40 %), followed by groin 154 (32.5 %) and neck 130 (27.5 %). Adjuvant radiotherapy to the nodal basin was delivered to 134 patients (28 %). BMs occurred in 61 patients (12.9 %) with a median time of 13.87 months from dissection. No lymph node characteristics were significantly associated with the development of BMs including: nodal region (p = 0.72), nodal size (p = 0.08), number of involved nodes (p = 0.36), presence of extra-capsular spread (p = 0.47) and AJCC N stage. There was no significant association between primary ulceration (p = 0.37) or location and development of BMs. It appears that for patients with resected stage III melanoma there is no histopathological lymph node feature associated with the development of BMs. This highlights the importance of identifying molecular markers in nodal melanoma which may predict for BMs to further direct site-specific therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Eigentler TK, Figl A, Krex D, Mohr P, Mauch C, Rass K, Bostroem A, Heese O, Koelbl O, Garbe C et al (2011) Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer 117(8):1697–1703

    Article  PubMed  Google Scholar 

  2. Patel JK, Didolkar MS, Pickren JW, Moore RH (1978) Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg 135(6):807–810

    Article  CAS  PubMed  Google Scholar 

  3. Carlino MS, Fogarty GB, Long GV (2012) Treatment of melanoma brain metastases: a new paradigm. Cancer J 18(2):208–212

    Article  CAS  PubMed  Google Scholar 

  4. Sampson JH, Carter JH Jr, Friedman AH, Seigler HF (1998) Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 88(1):11–20

    Article  CAS  PubMed  Google Scholar 

  5. Muacevic A, Wowra B, Siefert A, Tonn JC, Steiger HJ, Kreth FW (2008) Microsurgery plus whole brain irradiation versus gamma knife surgery alone for treatment of single metastases to the brain: a randomized controlled multicentre phase III trial. J Neurooncol 87(3):299–307

    Article  PubMed  Google Scholar 

  6. Dummer R, Rinderknecht J, Goldinger SM, et al (2011) An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases. J Clin Oncol 29[suppl] (Abstract 8548)

  7. Long GV, Kefford RF, Carr PJA, et al (2010) Phase I/II study of GSK2118436, a selective inhibitor of V600 mutant (Mut) BRAF kinase: evidence of activity in melanoma brain metastases (Mets). Ann Oncol (Abstract LBA 27)

  8. Fonkem E, Uhlmann EJ, Floyd SR, Mahadevan A, Kasper E, Eton O, Wong ET (2012) Melanoma brain metastasis: overview of current management and emerging targeted therapies. Expert Rev Neurother 12(10):1207–1215

    Article  CAS  PubMed  Google Scholar 

  9. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF et al (2012) Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13(5):459–465

    Article  CAS  PubMed  Google Scholar 

  10. Coit DG, Andtbacka R, Bichakjian CK, Dilawari RA, Dimaio D, Guild V, Halpern AC, Hodi FS, Kashani-Sabet M, Lange JR et al (2009) Melanoma. J Natl Compr Cancer Netw 7(3):250–275

    CAS  Google Scholar 

  11. Burmeister BH, Henderson MA, Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, Scolyer RA, Carruthers S et al (2012) Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol 13(6):589–597

    Article  PubMed  Google Scholar 

  12. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199–6206

    Article  PubMed  Google Scholar 

  13. Langer CJ, Mehta MP (2005) Current management of brain metastases, with a focus on systemic options. J Clin Oncol 23(25):6207–6219

    Article  CAS  PubMed  Google Scholar 

  14. Bullard DE, Cox EB, Seigler HF (1981) Central nervous system metastases in malignant melanoma. Neurosurgery 8(1):26–30

    Article  CAS  PubMed  Google Scholar 

  15. Zakrzewski J, Geraghty LN, Rose AE, Christos PJ, Mazumdar M, Polsky D, Shapiro R, Berman R, Darvishian F, Hernando E et al (2011) Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. Cancer 117(8):1711–1720

    Article  PubMed Central  PubMed  Google Scholar 

  16. Daryanani D, Plukker JT, de Jong MA, Haaxma-Reiche H, Nap R, Kuiper H, Hoekstra HJ (2005) Increased incidence of brain metastases in cutaneous head and neck melanoma. Melanoma Res 15(2):119–124

    Article  PubMed  Google Scholar 

  17. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM et al (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American joint committee on cancer melanoma staging system. J Clin Oncol 19(16):3622–3634

    CAS  PubMed  Google Scholar 

  18. Vihinen P, Koskivuo I, Syrjanen K, Tervahartiala T, Sorsa T, Pyrhonen S (2008) Serum matrix metalloproteinase-8 is associated with ulceration and vascular invasion of malignant melanoma. Melanoma Res 18(4):268–273

    Article  CAS  PubMed  Google Scholar 

  19. Van de Vrie W, Eggermont AM, Van Putten WL, Wiggers T (1993) Therapeutic lymphadenectomy in melanomas of the head and neck. Head Neck 15(5):377–381

    Article  PubMed  Google Scholar 

  20. Fogarty G, Morton RL, Vardy J, Nowak AK, Mandel C, Forder PM, Hong A, Hruby G, Burmeister B, Shivalingam B et al (2011) Whole brain radiotherapy after local treatment of brain metastases in melanoma patients—a randomised phase III trial. BMC cancer 11:142

    Article  PubMed Central  PubMed  Google Scholar 

  21. Carella RJ, Gelber R, Hendrickson F, Berry HC, Cooper JS (1980) Value of radiation therapy in the management of patients with cerebral metastases from malignant melanoma: radiation therapy oncology group brain metastases study I and II. Cancer 45(4):679–683

    Article  CAS  PubMed  Google Scholar 

  22. Romano E, Scordo M, Dusza SW, Coit DG, Chapman PB (2010) Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. JClin Oncol 28(18):3042–3047

    Article  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, QLD, 4102, Australia

    James E. Jackson, Bryan H. Burmeister, Elizabeth A. Burmeister, Matthew C. Foote & Janelle A. Meakin

  2. University of Queensland, St Lucia, QLD, 4072, Australia

    James E. Jackson, Bryan H. Burmeister, Elizabeth A. Burmeister, Matthew C. Foote & B. Mark Smithers

  3. Department of Upper Gastrointestinal and Soft Tissue Surgery, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, QLD, 4102, Australia

    Janine M. Thomas & B. Mark Smithers

Authors
  1. James E. Jackson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bryan H. Burmeister
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elizabeth A. Burmeister
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Matthew C. Foote
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Janine M. Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Janelle A. Meakin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B. Mark Smithers
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James E. Jackson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jackson, J.E., Burmeister, B.H., Burmeister, E.A. et al. Melanoma brain metastases: the impact of nodal disease. Clin Exp Metastasis 31, 81–85 (2014). https://doi.org/10.1007/s10585-013-9611-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10585-013-9611-8

Keywords

Search

Navigation